- Home
- MX vs NKTX Comparison
MX vs NKTX Comparison
Compare MX & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MX
- NKTX
- Stock Information
- Founded
- MX 2003
- NKTX 2015
- Country
- MX South Korea
- NKTX United States
- Employees
- MX N/A
- NKTX N/A
- Industry
- MX Semiconductors
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- MX Technology
- NKTX Health Care
- Exchange
- MX Nasdaq
- NKTX Nasdaq
- Market Cap
- MX 112.8M
- NKTX 123.5M
- IPO Year
- MX N/A
- NKTX 2020
- Fundamental
- Price
- MX $3.08
- NKTX $2.42
- Analyst Decision
- MX Strong Buy
- NKTX Strong Buy
- Analyst Count
- MX 2
- NKTX 5
- Target Price
- MX $5.75
- NKTX $13.50
- AVG Volume (30 Days)
- MX 235.5K
- NKTX 1.2M
- Earning Date
- MX 11-03-2025
- NKTX 11-07-2025
- Dividend Yield
- MX N/A
- NKTX N/A
- EPS Growth
- MX N/A
- NKTX N/A
- EPS
- MX N/A
- NKTX N/A
- Revenue
- MX $234,243,000.00
- NKTX N/A
- Revenue This Year
- MX N/A
- NKTX N/A
- Revenue Next Year
- MX $7.05
- NKTX N/A
- P/E Ratio
- MX N/A
- NKTX N/A
- Revenue Growth
- MX 16.02
- NKTX N/A
- 52 Week Low
- MX $2.51
- NKTX $1.31
- 52 Week High
- MX $5.16
- NKTX $3.92
- Technical
- Relative Strength Index (RSI)
- MX 47.38
- NKTX 56.99
- Support Level
- MX $2.96
- NKTX $2.17
- Resistance Level
- MX $3.15
- NKTX $2.74
- Average True Range (ATR)
- MX 0.11
- NKTX 0.20
- MACD
- MX -0.00
- NKTX 0.00
- Stochastic Oscillator
- MX 35.77
- NKTX 59.03
About MX Magnachip Semiconductor Corporation
MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The company operates in two segments namely, Transitional Fab 3 foundry services and Standard products business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.